UA120587C2 - Спосіб лікування алергічного риніту з використанням комбінації мометазону та олопатадину - Google Patents

Спосіб лікування алергічного риніту з використанням комбінації мометазону та олопатадину Download PDF

Info

Publication number
UA120587C2
UA120587C2 UAA201507124A UAA201507124A UA120587C2 UA 120587 C2 UA120587 C2 UA 120587C2 UA A201507124 A UAA201507124 A UA A201507124A UA A201507124 A UAA201507124 A UA A201507124A UA 120587 C2 UA120587 C2 UA 120587C2
Authority
UA
Ukraine
Prior art keywords
mcg
treatment
olopatadine
allergic rhinitis
mometasone
Prior art date
Application number
UAA201507124A
Other languages
English (en)
Ukrainian (uk)
Inventor
Джоші Неєліма Хайраткар
Джоши Нэелима Хайраткар
Абхай Кулкарні
Абхай КУЛКАРНИ
Дінеш Прадіп Вал
Динэш Прадип Вал
Вікрам Мансінгх Бхослі
Викрам Мансингх БХОСЛИ
Піюш Агарвал
Пиюш Агарвал
Патрік Кеохейн
Патрик Кеохэйн
Судіш К. Тантрі
Судиш К. ТАНТРИ
Чед О
Чэд О
Original Assignee
Гленмарк Спешіалті С.А.
Глэнмарк Спэшиалти С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гленмарк Спешіалті С.А., Глэнмарк Спэшиалти С.А. filed Critical Гленмарк Спешіалті С.А.
Publication of UA120587C2 publication Critical patent/UA120587C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
UAA201507124A 2013-10-04 2014-10-03 Спосіб лікування алергічного риніту з використанням комбінації мометазону та олопатадину UA120587C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3174MU2013 2013-10-04
PCT/IB2014/065035 WO2015049665A1 (en) 2013-10-04 2014-10-03 Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Publications (1)

Publication Number Publication Date
UA120587C2 true UA120587C2 (uk) 2020-01-10

Family

ID=51982657

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201507124A UA120587C2 (uk) 2013-10-04 2014-10-03 Спосіб лікування алергічного риніту з використанням комбінації мометазону та олопатадину

Country Status (12)

Country Link
US (1) US10646500B2 (enExample)
EP (2) EP2922553B1 (enExample)
JP (3) JP6419195B2 (enExample)
CN (2) CN112773808A (enExample)
HK (1) HK1215674A1 (enExample)
MX (2) MX2015009429A (enExample)
MY (1) MY176808A (enExample)
PH (1) PH12015502302A1 (enExample)
RU (1) RU2686670C2 (enExample)
UA (1) UA120587C2 (enExample)
WO (1) WO2015049665A1 (enExample)
ZA (1) ZA201504740B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10646500B2 (en) * 2013-10-04 2020-05-12 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
AU2018260934B2 (en) * 2017-06-28 2023-10-19 Glenmark Specialty S.A. Dispensing device and pharmaceutical compositions for the treatment of rhinitis
HRP20250411T1 (hr) * 2018-02-23 2025-07-18 Glenmark Specialty S.A. Liječenje alergijskog rinitisa kod pedijatrijskih subjekata kombinacijom mometazona i olopatadina
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
ES2284531T3 (es) 1999-10-08 2007-11-16 Schering Corporation Tratamiento nasal topico usando desloratadina y furoato de mometasona.
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
BR0316203A (pt) * 2002-11-12 2005-10-04 Alcon Inc Uso de um agente antialérgico e um esteróide para tratar rinite alérgica
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
DK1814538T3 (da) 2004-11-24 2009-11-02 Alcon Inc Fremgangsmåde til administration af næsespray
BRPI0615032A2 (pt) * 2005-09-01 2011-04-26 Biolipox Ab composição farmacêutica, processo para a preparação da mesma, e, uso de uma composição
US20120121653A1 (en) 2005-12-02 2012-05-17 Elan Pharma International Limited Novel mometasone compositions and methods of making and using the same
JP5185109B2 (ja) 2006-04-21 2013-04-17 東興薬品工業株式会社 スプレー用ゲルタイプ皮膚・粘膜付着型製剤およびそれを用いた投与システム
CN106038481A (zh) * 2007-06-28 2016-10-26 锡德克斯药物公司 皮质类固醇水溶液的鼻部和眼部给药
RU2011101151A (ru) 2008-07-15 2012-07-20 Шеринг Корпорейшн (US) Интраназальные композиции, содержащие деконгестант и кортикостероид
WO2010025236A1 (en) 2008-08-27 2010-03-04 Alexander Goldin Composition and method for treating colds
AU2010273347B2 (en) 2009-07-17 2015-04-30 Alcon Research, Ltd. Olopatadine nasal spray regimen for children
CN102078326A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有聚维酮碘与糠酸莫米松的局部使用组合物
CN102078285A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有皮质激素和h1受体拮抗剂的鼻用原位凝胶
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
WO2012094283A2 (en) 2011-01-04 2012-07-12 Ista Pharmaceuticals, Inc. Bepotastine compositions
MX2015005081A (es) 2012-10-25 2015-07-17 Novozymes As Metodo mejorado para el lavado manual de la vajilla.
KR20140081925A (ko) * 2012-12-12 2014-07-02 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제
MY191380A (en) 2013-09-13 2022-06-21 Glenmark Specialty Sa Stabilized fixed dose drug composition having mometasone and olopatadine
US10646500B2 (en) * 2013-10-04 2020-05-12 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine

Also Published As

Publication number Publication date
EP2922553A1 (en) 2015-09-30
JP2018123157A (ja) 2018-08-09
MY176808A (en) 2020-08-21
WO2015049665A1 (en) 2015-04-09
US10646500B2 (en) 2020-05-12
RU2015128496A3 (enExample) 2018-06-19
RU2686670C2 (ru) 2019-04-30
EP2922553B1 (en) 2026-05-06
US20150099725A1 (en) 2015-04-09
HK1215674A1 (zh) 2016-09-09
EP4272839A3 (en) 2024-01-03
ZA201504740B (en) 2016-10-26
JP6419195B2 (ja) 2018-11-07
PH12015502302B1 (en) 2016-02-15
MX2015009429A (es) 2015-10-09
RU2015128496A (ru) 2017-11-13
JP6768733B2 (ja) 2020-10-14
CN105792828A (zh) 2016-07-20
PH12015502302A1 (en) 2016-02-15
RU2019104453A (ru) 2019-03-28
CN112773808A (zh) 2021-05-11
JP2020097624A (ja) 2020-06-25
JP2016531949A (ja) 2016-10-13
EP4272839A2 (en) 2023-11-08
MX2020003035A (es) 2020-07-22

Similar Documents

Publication Publication Date Title
RU2686670C2 (ru) Лечение аллергического ринита с использованием комбинации мометазона и олопатадина
US20200323843A1 (en) Use of levocetirizine and montelukast in the treatment of viral infection caused by coronavirus
Ratner et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar
US9023815B2 (en) Method for treating rhinitis and sinusitis by rhamnolipids
US20230210861A1 (en) Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
JP6313413B2 (ja) アナフィラキシーの処置におけるレボセチリジン及びモンテルカストの使用
JP2022546456A (ja) 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン
US10548907B2 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Abelson et al. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model
WO2021202332A1 (en) Aqueous formulations containing povidone iodine for effective treatment and prevention of virus infections
JP7621668B2 (ja) 疾患の処置用の２－（ジエチルアミノ）エチル２－（４－イソブチルフェニル）プロピオネートの局所投与
RU2799761C2 (ru) Лечение аллергического ринита с использованием комбинации мометазона и олопатадина
HK40095786A (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US20060287364A1 (en) Methods of prevention of infection with HIV/AIDS, venereal disease and influenza
RU2432951C2 (ru) Фамцикловир для лечения рецидивирующего простого герпеса при однодневном введении
HK40090283B (en) Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
HK40087315A (zh) 以2-(二乙基氨基)乙基2-(4-异丁基苯基)丙酸酯局部给药治疗疾病
Parikh et al. A Randomized Comparative Study of “New Nasivion Care Drops” in Patients with Nasal Congestion Due to Acute Exacerbation of Allergic Rhinitis
Langade A Randomized Comparative Study of" New Nasivion Care Drops" in Patients with Nasal Congestion Due to Acute Exacerbation of...
HK1199815B (en) Levocetirizine and montelukast for the treatment of influenza and common cold
JP2016535793A (ja) 口腔アレルギー症候群の予防および治療のための製剤および方法